Island Pharmaceuticals Limited (ILA.AX)
AUD 0.17
(3.03%)
AUD 0.17
(3.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.04 Million AUD | 296.3% |
| 2023 | 263.84 Thousand AUD | -54.57% |
| 2022 | 580.73 Thousand AUD | 145.21% |
| 2021 | 236.83 Thousand AUD | 35037.98% |
| 2020 | 674.00 AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.04 Million AUD | -7.33% |
| 2024 Q2 | 1.12 Million AUD | 0.0% |
| 2024 Q1 | 1.12 Million AUD | 94.3% |
| 2024 Q4 | 1.04 Million AUD | 0.0% |
| 2024 FY | 1.04 Million AUD | 296.3% |
| 2023 Q2 | 678.09 Thousand AUD | 0.0% |
| 2023 Q1 | 678.09 Thousand AUD | 16.76% |
| 2023 Q3 | 263.84 Thousand AUD | -61.09% |
| 2023 Q4 | 580.73 Thousand AUD | 120.1% |
| 2023 FY | 263.84 Thousand AUD | -54.57% |
| 2022 Q2 | 110.69 Thousand AUD | 0.0% |
| 2022 Q1 | 110.69 Thousand AUD | -53.26% |
| 2022 FY | 580.73 Thousand AUD | 145.21% |
| 2022 Q4 | 580.73 Thousand AUD | 0.0% |
| 2022 Q3 | 580.73 Thousand AUD | 424.61% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 FY | 236.83 Thousand AUD | 35037.98% |
| 2021 Q4 | 236.83 Thousand AUD | 0.0% |
| 2021 Q3 | 236.82 Thousand AUD | 0.0% |
| 2020 FY | 674.00 AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -240.762% |
| BTC Health Limited | 203.94 Thousand AUD | -412.691% |
| CSL Limited | 27.88 Billion AUD | 99.996% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 87.45% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 96.281% |
| Orthocell Limited | 22.08 Million AUD | 95.265% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | 35.691% |
| Race Oncology Limited | 1.91 Million AUD | 45.439% |
| Starpharma Holdings Limited | 8.69 Million AUD | 87.979% |
| AdAlta Limited | 3.54 Million AUD | 70.484% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 88.825% |
| Memphasys Limited | 5.59 Million AUD | 81.303% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -1120.34% |
| Acrux Limited | 5.68 Million AUD | 81.614% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -183.793% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 71.983% |
| Cynata Therapeutics Limited | 1.17 Million AUD | 10.711% |
| Nyrada Inc. | 855.63 Thousand AUD | -22.205% |
| PharmAust Limited | 896.6 Thousand AUD | -16.62% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 97.66% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 49.159% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 80.728% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 69.487% |
| Biome Australia Limited | 5.37 Million AUD | 80.54% |
| Biotron Limited | 737.5 Thousand AUD | -41.778% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 91.833% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 75.276% |
| Immutep Limited | 10.97 Million AUD | 90.477% |
| Imugene Limited | 33.14 Million AUD | 96.845% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -142.25% |
| Noxopharm Limited | 1.28 Million AUD | 18.857% |
| Patrys Limited | 691.36 Thousand AUD | -51.241% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 55.038% |
| PYC Therapeutics Limited | 10.18 Million AUD | 89.733% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.581% |
| Dimerix Limited | 13.89 Million AUD | 92.474% |
| Hexima Limited | 248.67 Thousand AUD | -320.487% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 97.555% |
| Nanollose Limited | 465.64 Thousand AUD | -124.555% |
| Tissue Repair Ltd | 1.35 Million AUD | 22.598% |
| AnteoTech Limited | 4.07 Million AUD | 74.342% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 70.828% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 93.421% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -11.055% |
| Actinogen Medical Limited | 1.61 Million AUD | 35.27% |
| Immuron Limited | 2.84 Million AUD | 63.189% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 56.912% |